Stay updated on Pembrolizumab in NSCLC with PS 2 Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.

Latest updates to the Pembrolizumab in NSCLC with PS 2 Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed descriptions of a clinical trial for pembrolizumab in patients with Non-Small Cell Lung Cancer, while retaining key identifiers and collaborators associated with the study.SummaryDifference20%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 10, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.5%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check80 days agoChange DetectedThe webpage has been updated to include new results and timelines for the clinical trials involving pembrolizumab, specifically focusing on patients with performance status 2. Key updates include the addition of new reporting dates and a commitment to data sharing for research purposes.SummaryDifference18%
Stay in the know with updates to Pembrolizumab in NSCLC with PS 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.